Key result
Evaluating novel cardiovascular biomarkers for clinical use requires assessing their reproducibility, incremental value, and ability to assist in patient care.
Proposes three criteria for evaluating novel cardiovascular biomarkers for clinical use: reproducibility, incremental information, and clinical utility.
proposed three criteria by which to evaluate novel cardiovascular biomarkers for clinical use. First, can the biomarker be measured reproducibly in clinical laboratories? Second, does the biomarker add incremental new information to existing tests? And third, will the measurement of the biomarker assist in the care of patients? The answer to the third question often distinguishes a research tool from a clinical instrument.
No takes yet. Share an insight, caveat, or question.
Cunningham et al. (2022) conducted an editorial in Cardiovascular disease. Cardiovascular biomarkers was evaluated. Evaluating novel cardiovascular biomarkers for clinical use requires assessing their reproducibility, incremental value, and ability to assist in patient care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: